Susan Heimer

  1. Home
  2. California
  3. Touro University California
  4. Susan Heimer
Susan Heimer

Susan R. Heimer

  • Courses0
  • Reviews0
Rate This Professor

Social Profile:

Join to see

Biography

Touro University California - Pharmaceutical Sciences

Associate Professor at Touro University California
Higher Education
Susan
Heimer
Vallejo, California
Associated Professor in Biological and Pharmaceutical Sciences. Areas of teaching expertise include medical microbiology, infectious diseases, and ocular pharmacology. Research interests include ocular inflammation arising from infections, rosacea, and dry eye syndrome.

Experience

  • University of Maryland Baltimore

    Postdoctoral Researcher

    Susan worked at University of Maryland Baltimore as a Postdoctoral Researcher

  • University of Maryland Baltimore

    Research Assistant

    Susan worked at University of Maryland Baltimore as a Research Assistant

  • Harvard Medical School

    Postdoctoral Research Fellow

    Susan worked at Harvard Medical School as a Postdoctoral Research Fellow

  • UC Berkeley

    Visiting Research Scholar

    Susan worked at UC Berkeley as a Visiting Research Scholar

Education

  • University of Maryland Baltimore

    Doctor of Philosophy (PhD)

    Biochemistry and Molecular Biology

  • University of Maryland Baltimore

    Postdoctoral Researcher



  • University of Maryland Baltimore

    Research Assistant



Publications

  • Surfactant protein D contributes to ocular defense against Pseudomonas aeruginosa in a murine model of dry eye disease

    PLoS One

    Dry eye disease can cause ocular surface inflammation that disrupts the corneal epithelial barrier. While dry eye patients are known to have an increased risk of corneal infection, it is not known whether there is a direct causal relationship between these two conditions. Here, we tested the hypothesis that experimentally-induced dry eye (EDE) increases susceptibility to corneal infection using a mouse model. In doing so, we also examined the role of surfactant protein D (SP-D), which we have previously shown is involved in corneal defense against infection. Scopolamine injections and fan-driven air were used to cause EDE in C57BL/6 or Black Swiss mice (wild-type and SP-D gene-knockout). Controls received PBS injections and were housed normally. After 5 or 10 days, otherwise uninjured corneas were inoculated with 109 cfu of Pseudomonas aeruginosa strain PAO1. Anesthesia was maintained for 3 h post-inoculation. Viable bacteria were quantified in ocular surface washes and corneal homogenates 6 h post-inoculation. SP-D was measured by Western immunoblot, and corneal pathology assessed from 6 h to 4 days. EDE mice showed reduced tear volumes after 5 and 10 days (each by ∼75%, p<0.001) and showed fluorescein staining (i.e. epithelial disruption). Surprisingly, there was no significant difference in corneal pathology between EDE mice and controls (∼10–14% incidence). Before bacterial inoculation, EDE mice showed elevated SP-D in ocular washes. After inoculation, fewer bacteria were recovered from ocular washes of EDE mice (<2% of controls, p = 0.0004). Furthermore, SP-D knockout mice showed a significant increase in P. aeruginosa corneal colonization under EDE conditions. Taken together, these data suggest that SP-D contributes to corneal defense against P. aeruginosa colonization and infection in EDE despite the loss of barrier function to fluorescein.

  • Surfactant protein D contributes to ocular defense against Pseudomonas aeruginosa in a murine model of dry eye disease

    PLoS One

    Dry eye disease can cause ocular surface inflammation that disrupts the corneal epithelial barrier. While dry eye patients are known to have an increased risk of corneal infection, it is not known whether there is a direct causal relationship between these two conditions. Here, we tested the hypothesis that experimentally-induced dry eye (EDE) increases susceptibility to corneal infection using a mouse model. In doing so, we also examined the role of surfactant protein D (SP-D), which we have previously shown is involved in corneal defense against infection. Scopolamine injections and fan-driven air were used to cause EDE in C57BL/6 or Black Swiss mice (wild-type and SP-D gene-knockout). Controls received PBS injections and were housed normally. After 5 or 10 days, otherwise uninjured corneas were inoculated with 109 cfu of Pseudomonas aeruginosa strain PAO1. Anesthesia was maintained for 3 h post-inoculation. Viable bacteria were quantified in ocular surface washes and corneal homogenates 6 h post-inoculation. SP-D was measured by Western immunoblot, and corneal pathology assessed from 6 h to 4 days. EDE mice showed reduced tear volumes after 5 and 10 days (each by ∼75%, p<0.001) and showed fluorescein staining (i.e. epithelial disruption). Surprisingly, there was no significant difference in corneal pathology between EDE mice and controls (∼10–14% incidence). Before bacterial inoculation, EDE mice showed elevated SP-D in ocular washes. After inoculation, fewer bacteria were recovered from ocular washes of EDE mice (<2% of controls, p = 0.0004). Furthermore, SP-D knockout mice showed a significant increase in P. aeruginosa corneal colonization under EDE conditions. Taken together, these data suggest that SP-D contributes to corneal defense against P. aeruginosa colonization and infection in EDE despite the loss of barrier function to fluorescein.

  • Pseudomonas aeruginosa utilizes the Type III secreted toxin ExoS to avoid acidified compartments within epithelial cells

    PLoS One

    Invasive Pseudomonas aeruginosa (PA) are able to invade epithelial cells and form plasma membrane bleb-niches for intracellular survival. This survival strategy seems to require the ADP-ribosyltransferase (ADPr) activity of ExoS, a PA type III secretion system (T3SS) effector protein. PA mutants lacking the complete T3SS traffic appear to traffick to perinuclear vacuoles. Here, we tested whether the T3SS, via the ADPr activity of ExoS, allows PA to evade acidic vacuoles that otherwise suppress its intracellular viability. The acidification state of bacteria-occupied vacuoles within infected corneal epithelial cells was studied using LysoTracker to visualize acidic, lysosomal vacuoles. Steady state analysis showed that within cells wild-type PAO1 localized to both membrane bleb-niches and vacuoles, while both exsA (transcriptional activator) and popB (effector translocation) T3SS mutants were only found in vacuoles. The acidification state of occupied vacuoles suggested a relationship with ExoS expression, i.e. vacuoles occupied by the exsA mutant (unable to express ExoS) were more often acidified than either popB mutant or wild-type PAO1 occupied vacuoles (p < 0.001). An exoS-gfp reporter construct pJNE05 confirmed that high exoS transcriptional output coincided with low occupation of acidified vacuoles, and vice versa, for both popB mutants and wild-type bacteria. Complementation of a triple effector null mutant of PAO1 with exoS (pUCPexoS) reduced the number of acidified bacteria-occupied vacuoles per cell; pUCPexoSE381D which lacks ADPr activity did not. The H+-ATPase inhibitor bafilomycin rescued intracellular replication to wild-type levels for exsA mutants, showing its viability is suppressed by vacuolar acidification. Taken together, the data show that ExoS ADPr activity suppresses vacuolar acidification and variability in ExoS expression can influence the fate of individual intracellular bacteria, even within the same cell.